Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) and Oncobiologics (NASDAQ:OTLK – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.
Valuation & Earnings
This table compares Celldex Therapeutics and Oncobiologics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celldex Therapeutics | $158,000.00 | 14,194.86 | -$258.76 million | ($4.30) | -6.64 |
| Oncobiologics | -$1.16 million | -82.86 | -$62.42 million | ($0.77) | -0.51 |
Oncobiologics has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations for Celldex Therapeutics and Oncobiologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celldex Therapeutics | 1 | 1 | 11 | 0 | 2.77 |
| Oncobiologics | 1 | 2 | 2 | 0 | 2.20 |
Celldex Therapeutics presently has a consensus price target of $64.08, indicating a potential upside of 124.48%. Oncobiologics has a consensus price target of $5.20, indicating a potential upside of 1,213.13%. Given Oncobiologics’ higher possible upside, analysts clearly believe Oncobiologics is more favorable than Celldex Therapeutics.
Risk & Volatility
Celldex Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Profitability
This table compares Celldex Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celldex Therapeutics | N/A | -52.66% | -47.58% |
| Oncobiologics | N/A | N/A | -254.82% |
Insider & Institutional Ownership
11.2% of Oncobiologics shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Celldex Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.
About Oncobiologics
Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
